• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Duggan Robert W bought $1,112,898 worth of shares (116,656 units at $9.54), increasing direct ownership by 0.32% to 36,876,062 units (SEC Form 4)

    12/12/23 7:28:10 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DUGGAN ROBERT W

    (Last) (First) (Middle)
    3957 POINT EDEN WAY

    (Street)
    HAYWARD CA 94545

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Pulse Biosciences, Inc. [ PLSE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/08/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/08/2023 P 116,656 A $9.54(1) 36,876,062 D
    Common Stock 351,565 I See footnote(2)
    Common Stock 492,069 I See footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Volume-weighted average price.
    2. Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder.
    3. Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
    /s/ Kenneth B. Stratton, as Attorney-in-Fact 12/12/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PLSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. Pulse Biosciences' Management is scheduled to present on Wednesday, May 14, 2025, at 5:00 pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as we

      5/6/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on April 21, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 19,500 shares of Company common stock. The Company's independent

      4/25/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

      Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

      2/4/25 8:00:00 AM ET
      $AXTA
      $PLSE
      $TFX
      Paints/Coatings
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

      Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

      10/30/24 4:02:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

      Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

      8/12/24 4:01:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

      SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      7/8/24 3:30:25 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/14/23 7:21:15 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/4/23 5:18:06 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 8:02:46 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 6:05:11 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/13/24 7:30:48 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zanganeh Mahkam exercised 60,242 in-the-money shares at a strike of $11.00, increasing direct ownership by 9% to 725,395 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      2/11/25 6:20:57 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Laviolette Paul A

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      1/13/25 7:45:33 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Barrett Burke Thomas sold $871,000 worth of shares (50,000 units at $17.42), decreasing direct ownership by 44% to 63,172 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/20/24 5:00:42 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PLSE
    Financials

    Live finance-specific insights

    See more
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

      2/10/22 6:14:40 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

      11/16/21 9:11:22 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Stephens & Co. initiated coverage on Pulse Biosciences with a new price target

      Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00

      7/27/21 5:53:59 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelect

      4/24/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

      3/27/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pulse Biosciences Inc

      10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 5:24:22 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 4:22:58 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Pulse Biosciences Inc

      10-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      4/30/25 9:08:54 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care